Rite Aid (RAD) Gets a Sell Rating from Deutsche Bank

In a report issued on July 18, George Hill from Deutsche Bank maintained a Sell rating on Rite Aid (RADResearch Report). The company’s shares closed last Tuesday at $7.52.

According to, Hill is a 5-star analyst with an average return of 7.3% and a 55.2% success rate. Hill covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Molina Healthcare, and 1Life Healthcare.

The the analyst consensus on Rite Aid is currently a Moderate Sell rating.

See Insiders’ Hot Stocks on TipRanks >>

Rite Aid’s market cap is currently $418.3M and has a P/E ratio of -0.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through the Retail Pharmacy and Pharmacy Services business segments. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass in September 1962 and is headquartered in Camp Hill, PA.

Read More on RAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More